AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

NCT05678933 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T-cell Lymphoma Targeted Therapy

Interventions

DRUG: Azacitidine
DRUG: Chidamide
DRUG: Cyclophosphamide
DRUG: Epirubicin
DRUG: Vincristine
DRUG: Prednisone

Sponsor

Tianjin Medical University Cancer Institute and Hospital